A Phase 2 Study Of PF-00232798 In HIV Positive Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions
HIV
Interventions
DRUG

PF-00232798

Solution, 20 mg. once daily, 10 days

DRUG

PF-00232798

Solution, 150 mg. once daily, 10 days

DRUG

PF-00232798

Solution, 5 mg. once daily, 10 days

DRUG

PF-00232798

Solution, 40 mg. once daily, 10 days

DRUG

PF-00232798

Solution, 300 mg. once daily, 10 days

DRUG

PF-00232798

Solution, 400 mg. once daily, 10 days

Trial Locations (2)

50937

Pfizer Investigational Site, Cologne

60590

Pfizer Investigational Site, Frankfurt am Main

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY